Novel Two-Prong Biologic Shows Promise in Asthma

(MedPage Today) -- The unique dual inflammation blockade of investigational lunsekimig showed promise for moderate-to-severe asthma in the phase II AIRCULES study. Targeting both thymic stromal lymphopoietin (TSLP) and interleukin (IL)-13, lunsekimig...